Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2011

View Archived Issues

Zoonotic paramyxovirus-neutralizing antibody evaluated in nonhuman primates

Promising preclinical data disclosed on new antiobesity therapy

New exportin-1 inhibitors show preclinical potential in MCL and MM

Scientists reveal new potential use for sitagliptin in cord blood transplant

Clinical data reported on PR-104 in leukemia

Intellikine patents new protein kinase inhibitors

Novel guanylyl cyclase activators prepared by Bayer Schering Pharma

Targacept synthesizes novel nicotinic acetylcholine receptor ligands

New metabotropic glutamate mGlu5 receptor positive allosteric modulators reported

FDA grants new approval for Isentress

Novel antibacterial agents designed in Japan

ThromboGenics submits BLA for ocriplasmin

AVEO Pharmaceuticals begins enrollment in tivozanib trial

Roche submits MAA for vismodegib

Japan Tobacco and Gilead Sciences enter licensing agreement

FDA advisory committee sets Qnexa NDA review date

New European approval for Avastin

Repros Therapeutics reports phase IIb data on Androxal

Karo Bio and Pfizer to jointly develop new drugs for autoimmune diseases

Xenome raises funds for development of peptide pain therapy

Ventrus BioSciences completes enrollment in phase III diltiazem trial

ProteoTech and GSK enter agreement

Researchers begin first clinical study of new HIV vaccine

DV-1179 enters proof-of-mechanism trial

Zogenix completes pre-NDA meetings with FDA for Zohydro

Promising phase III data reported on therapy for opioid-induced constipation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...